Calcitonin News
Protective Effect of Proteinase-Activated Receptor 2 Activation on Motility Impairment and Tissue Damage Induced by Intestinal Ischemia/Reperfusion in Rodents
We hypothesized that proteinase-activated receptor-2 (PAR2) modulates intestinal injuries induced by ischemia/reperfusion. Ischemia (1 hour) plus reperfusion (6 hours) significantly delayed gastrointestinal transit (GIT) compared...
Emisphere Reports Completion of Planned Preclinical Safety Studies for Oral Calcitonin Program
Emisphere Technologies, Inc. ("Emisphere", Nasdaq: EMIS) announced today that Novartis Pharma AG has notified Emisphere that Novartis Pharma AG has completed the planned preclinical safety studies for the oral calcitonin product...
Unigene Announces Results for the First Quarter of 2006
Revenue for the quarter ended March 31, 2006 was $387,000 compared to $588,000 for the quarter ended March 31, 2005. Unigene's net loss for the quarter ended March 31, 2006 was $3,243,000 or ($.04) per share compared to a net...
VasoGenix Pharmaceuticals and Cleveland Clinic Sign Phase I/II Safety and Efficacy Clinical Trial Agreement
VasoGenix Pharmaceuticals Inc. (www.vasogenix.net) announced today that it has entered into an agreement with Cleveland Clinic to utilize the Clinic's expertise in clinical cardiovascular research on the application of...
Engineering profession’s top organization elects Dr. Nicholas Peppas as member
Dr. Nicholas Peppas, professor of biomedical engineering, chemical engineering and pharmaceutics at The University of Texas at Austin, has been elected to membership in the National Academy of Engineering, widely considered the...